Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification: Analytical survey from 1997 to 2012

Tumor Biology

Volumn 34, Issue 4, 2013, Pages 2349-2355

  García Fernández, Antonio ^a,b   Chabrera, Carol ^c,d   García Font, Marc ^e   Fraile, Manel ^a   Gónzalez, Sonia ^a   Barco, Israel ^a   González, Clarisa ^a   Cirera, Lluís ^a   Veloso, Enrique ^a   Lain, José María ^f   Pessarrodona, Antoni ^a   Giménez, Nuria ^a,g  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT CATALÀ DE LA SALUT   (Spain)

^c Parc TecnoCampus   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^f HOSPITAL DE TERRASSA   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Breast neoplasms; ErbB 2 receptor; Estrogen receptors; Mortality; Progesterone receptors; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; METASTASIS; MORTALITY; PRIORITY JOURNAL; RADICAL RESECTION; TUMOR VOLUME;

EID: 84881480543     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0782-3     Document Type: Article

References (30)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-74.
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-23.
4. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109:123-39.
5. Phipps AL, Chlebowski RT, Prentice R, et al. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:454-63.
6. Dignam JJ, Dukic V, Anderson SL, et al. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat. 2009;116:595-602.
7. Aebi S, Sun Z, Braun D, et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol. 2011;22:1981-7.
8. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373-8.
9. Loi S, Sotiriou C, Haibe-Kains B, et al. Gene expression profiling identifies activated growth factor signalling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genet. 2009;37:1-9.
10. Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131:1061-6.
11. Sortiriou C, Phil D, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790-800.
12. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-47.
13. Caray LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-502.
14. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-76.
15. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008;10:R67.
16. García Fernández A, Fraile M, Giménez N, et al. Use of axillary ultrasound, ultrasound-fine needle aspiration biopsy and magnetic resonance imaging in the preoperative triage of breast cancer patients considered for sentinel node biopsy. Ultrasound Med Biol. 2011;37:16-22.
17. Wolters R, Regierer AC, Schwentner L, et al. A comparison of international breast cancer guidelines - do the national guidelines differ in treatment recommendations? Eur J Cancer. 2011;48:1-11.
18. Sanpaolo P, Barbieri V, Genovesi D. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol. 2011;37:876-82.
19. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 2011;13:221.
20. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009;15:593-602.
21. García Fernández A, Giménez N, Fraile M, et al. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010. Breast. 2012;21:366-73.
22. Eiermann W, Bergh J, Cardoso F, et al. Triple negative breast cancer: proposal for a pragmatic definition and implications for patient management and trial design. Breast. 2012;21:20-6.
23. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;16:2784-95.
24. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27:5700-5.
25. Grann VR, Troxel AB, Zojwalla NJ, et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005;103:2241-51.
26. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569-83.
27. Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer. 2008;112:737-47.
28. Regierer AC, Wolters R, Kurzeder C, et al. High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS? Breast Cancer Res Treat. 2011;128:273-81.
29. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-34.
30. Birner P, Oberhuber G, Stani J, et al. Austrian Breast & Colorectal Cancer Study Group: evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 2001;7:1669-75.